RMP-7, a bradykinin analog, has been shown to selectively open the blood-tumor barrier for the delivery of chemotherapeutic drugs to brain tumors. In contrast to bradykinin, RMP-7 has no hypotensive effects and has been approved for human use. This study was initiated to determine whether RMP-7 would open the blood-tumor barrier to virus vectors encoding tumor-killing genes in an experimental model. The herpes virus vector used, hrR3, which encodes virus thymidine kinase gene and the lacZ reporter gene, is defective in a gene encoding ribonucleotide reductase, replicates selectively in dividing tumor cells and not in postmitotic neural cells. It was determined that an optimum dose of RMP-7 (1.5-3.0 g/kg over 10 -15 minutes) enhanced viral delivery to brain tumors in rats bearing intracranial 9 L gliosarcomas when infused through the carotid artery immediately prior to virus vector application. Maximum expression of the lacZ reporter gene occurred at 3 days after intracarotid infusion. By 8 days, transgene expression was largely confined to tumor foci away from the main tumor mass. Viral delivery was essentially specific to tumor cells, with little transgene expression elsewhere in the brain. Minimal uptake and pathology was noted in the kidney, spleen, and liver. These findings indicate that intracarotid delivery of RMP-7 can augment the selective delivery of virus vectors to brain tumors in an experimental rat model, with the potential for application to human brain tumors.
M alignant gliomas are resistant to the conventional treatment modalities of surgery, radiation, and chemotherapy. The median survival for patients with glioblastoma multiform (GBM) is 1 year from the time of diagnosis. 1 Although the main mass of a tumor can be killed or growth-arrested, micrometastases near the infiltrating border usually lead to local recurrence and to the subsequent death of the patient. These small tumor foci develop a neovasculature that has a somewhat leaky blood-tumor barrier (BTB). 2 Disruption of the BTB to facilitate the delivery of therapeutic genes designed to kill dividing cells, such as tumor cells and tumor vessel endothelial cells, may provide a means to eradicate these new tumor foci.
Therapeutic genes can be delivered to tumors using both viral and nonviral vectors (reviewed in Ref. 3) . One approach uses a prodrug activating enzyme, such as herpes simplex virus type 1 thymidine kinase (HSV-tk), which renders transduced dividing cells susceptible to the prodrug ganciclovir (GCV). 4 -6 In this tumor killing paradigm, systemic GCV treatment results in local phosphorylation of GCV by HSV-tk, with subsequent cell death due to a disruption of DNA synthesis; cell death is accompanied by a bystander effect, in which the number of tumor cells killed is greater than the number of transduced tumor cells. 6 -10 This effect is mediated in part by the transfer of phosphorylated GCV from transduced to adjacent nontransduced tumor cells 11 as well as by an antitumoral response enhanced by paracrine effects of viral exposure 12 and an immune response to transfected tumor cells. 13, 14 The antitumor effect mediated by HSV-tk and GCV varies with the type of vector and the method of delivery to the brain tumor. Three routes of delivery have been used with HSV-1 vectors: direct intratumoral, intrathecal, and intravascular. 3 Direct inoculation of the herpes vector, hrR3, which replicates selectively in tumor cells in the brain, combined with GCV treatment, produced 50% long-term survival in rats with intracranial 9 L gliosarcoma tumors. 7 With intrathecal injection of the same vector followed by GCV treatment, 90% long-term survival was achieved in a similar model; however, this approach was limited by the narrow therapeutic index, due to associated toxicity resulting from inflammation in the cerebral spinal fluid. 15 The intravascular delivery of genes and drugs to the brain and to brain tumors is limited by the blood-brain barrier (BBB) and BTB, respectively, with the latter being somewhat leakier than the former. 2, 16 Hyperosmolar agents, such as mannitol, can transiently disrupt the BBB 17 and BTB, 18 allowing the delivery of chemotherapeutic agents, antibodies, and viruses. However, because osmotic disruption at least partially opens the normal BBB as well as the BTB, delivery of virus vectors 17 and other agents 18, 19 by this means can cause some toxicity to the normal brain. Other agents such as leukotrienes, adenosine, histamine, and bradykinin (BK) increase the permeability of brain tumor capillaries more than that of normal brain capillaries 20 -23 and may provide a more selective approach to gene therapy for brain tumors. In previous studies, the intra-arterial administration of BK was found to mediate the selective delivery of HSV and monocrystalline iron oxide nanocolloid particles to 9 L tumors in the rat brain. 24 RMP-7 (Alkermes Inc.) is an analog of BK with a longer half-life, greater potency in vivo, and specificity for the B 2 subclass of BK receptors; in addition, RMP-7 lacks the systemic hypotensive effects of BK. 25, 26 RMP-7 has been found to open the BTB to a greater extent than the BBB, allowing relatively specific delivery of therapeutic agents to brain tumors. 26 For example, intracarotid administration of RMP-7 enhanced the tumorspecific delivery of carboplatin when administered either intra-arterially or intravascularly and improved survival in a rat glioma model. 27 Recently, this therapeutic paradigm (intravascular delivery of carboplatin with RMP-7) has been introduced in phase I and II clinical trials. 28 -29 Here we demonstrate that intra-arterial infusion of RMP-7 significantly enhances the delivery of a herpes virus vector bearing the HSV-tk and lacZ genes to intracranial rat 9 L gliosarcomas, with virtually no infection of the normal brain and minimal infection of peripheral tissue.
MATERIALS AND METHODS

Virus stocks
The HSV mutant, hrR3, 30 was used for all studies. This mutant virus (provided by Dr. S. K. Weller, University of Connecticut, Farmington, Conn) encodes the Escherichia coli lacZ gene inserted into the HSV gene for the large subunit of ribonucleotide reductase. Both tk and lacZ genes are under the control of early virus promoters and consequently should be expressed at the same time during virus infection. Virus was grown on African green monkey kidney cells (Vero cells), titered by plaque assay, 31 and stored at Ϫ80°C in Dulbecco's modified Eagle's medium. Animals were injected intra-arterially with 1 ϫ 10 9 plaque-forming units (PFU) in saline or with saline alone in different volumes. Virus aliquots are kept on dry ice and warmed to 37°C immediately prior to carotid injection.
Animal studies
Adult male Fisher 344 CD rats (200 -250 g) were used for all studies. Experiments were carried out in accordance with the Animal Care Guidelines of Massachusetts General Hospital. Animals were checked twice daily for neurological deficits or other physiologically compromising signs. Rats were anesthetized with an intraperitoneal injection of ketamine and xylazine (0.5 mL of 0.9% NaCl containing 12.5 mg of Ketalar and 2.5 mg of Rompun) prior to tumor implantations and carotid cannulations.
Tumor implantation and carotid cannulation
On day 0, tumor implantation was performed essentially as described previously by Rainov et al. 24 A total of 40,000 9 L gliosarcoma cells in 2 L of phosphate-buffered saline (PBS) (pH ϭ 7.4) were injected into the right frontal lobe at a depth of 4 mm using a 10-L Hamilton syringe (Hamilton, Reno, Nev). At 5 days after tumor implantation (day 5), the rats underwent cannulation of the external carotid artery as described previously. 24 The external carotid artery was cannulated with polyurethane tubing (0.028 mm internal diameter, Becton Dickinson, Mountain View, Calif) and secured with 5-0 silk sutures and tissue adhesive (Vetbound, 3M, St. Paul, Minn). During infusions, body temperature was maintained using a heating pad. BK, RMP-7, or saline in volumes of 1.0 mL or 0.1 mL were infused over 15 minutes. Halfway through the infusion, a 100-L bolus of virus or saline was administered over 1 minute into the same carotid artery. For all studies, the instillation of RMP-7, BK, or saline over 10 -15 minutes is referred to as an infusion, whereas the relatively rapid administration of virus or vehicle over 1 minute is termed a bolus. After the completion of the infusion, the cannula was closed by bone wax; the animals were allowed to recover under observation.
Fixation and histochemistry
At times indicated, animals were sacrificed by anesthetic overdose (15 mg of sodium pentobarbital intraperitoneally) and subsequently perfused through the heart with ice-cold 4% paraformaldehyde in PBS. The brain, liver, kidney, and spleen were removed and placed in 4% paraformaldehyde-PBS overnight at 4°C, transferred to 30% sucrose-PBS for several days, frozen in liquid nitrogen, and stored at Ϫ80°C. Tissues were mounted in OCT compound (Miles, Elkhart, Ind) and sectioned at a 20-m thickness using a Jung cryostat (Cryocut 2800E, Leica, Deerfield, Ill). Sections were stained for ␤-galactosidase (␤-gal) expression by overnight incubation in 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) solution (pH ϭ 7.4) at 37°C using a modification 32 of the method of Turner et al. 33 Floating sections were mounted onto Superfrost Plus microscope slides (Fisher Scientific, Pittsburgh, Penn), air dried overnight at 4°C, and stained in neutral red (Fisher Scientific); sections were subsequently dehydrated through an ethanol series and xylene prior to mounting under coverslips with Cytoseal 60 mounting medium (Stephens Scientific, Riverdale, NJ).
Immunostaining with mouse anti-infected-cell protein-4-Ab was performed at a 1/3000 dilution; bound antibody was detected using biotinylated horse anti-mouse secondary antibody (Vector Labs, Burlingame, Calif) and subsequently visu-alized using an avidin-biotin-peroxidase reagent (ABC Elite kit, Vector Labs) as described elsewhere. 34 Drug and volume comparative study BK was compared with RMP-7 to assess any differences in vector delivery to 9 L intracranial tumors, implanted as described above, and infused with either a large volume (1 mL) or a small volume (0.1 mL) infusate. BK acetate (Sigma, St. Louis, Mo) or RMP-7 (Alkermes Inc.) in distilled water was infused into the carotid artery of rats and implanted on day 0 with 9 L gliosarcoma cells at 100 g/kg or 1.5 g/kg over 15 minutes, respectively. Rats were sacrificed at 2 days after infusion, and tissues were processed. Sections were evaluated under ϫ200-to 400-fold magnification in the central region in three random fields and in the peripheral region in three fields chosen to represent the highest, lowest, and median areas of positive cells. Positive and negative cells were counted in these six fields per tumor section, and the percentage of positive cells was averaged among them.
Statistical evaluation
Mean values, SE, and significance tests were calculated using SPSS for Windows Software (SPSS, Chicago, Ill).
RESULTS
Viral uptake in normal brain
First, preliminary experiments were carried out to determine whether the stereotactic injection procedure itself could facilitate viral entry into the normal rat brain. Three animals were sham-implanted with 2 L of vehicle (PBS) only instead of tumor cell suspension and were treated 5 days later with intra-arterial infusions of vehicle and virus injection. Animals were sacrificed after 2 days, and brains were processed for histochemistry. All animals showed some X-Gal staining of glial and endothelial capillary cells along the needle track, but no evidence of virus propagation (i.e., no plaque formation). Immunostaining for ICP4, which is an HSV immediate early gene product and a marker of virus infection, was also positive in normal cells along the implantation scar and essentially duplicated the X-Gal staining pattern. In addition, portions of the choroid plexus showed X-Gal-positive staining and immunostaining for ICP4. Normal blood vessels throughout the brain were not lacZ-or ICP4-positive in any of the animals. These preliminary studies indicated minimal disruption of the BBB by the intraparenchymal injection procedure itself. It was determined that X-Gal staining provides a reliable assessment of viral gene expression; consequently, X-Gal staining was used as the primary staining method for all subsequent experiments.
Dose response
To determine the appropriate dose of RMP-7 for a maximal uptake of HSV vectors into implanted 9 L brain tumors, varying doses of the drug were infused in combination with a 100-L bolus of either 1 ϫ 10 9 PFU virus or saline. A total of 11 animals were used in this study. The RMP-7 concentrations were 1.5, 3.0, 4.0, and 6.0 g/kg. At doses of Ͼ3.0 g/kg, animals died during the RMP-7 infusion, apparently from respiratory arrest followed by cardiac arrest. This toxicity did not appear related to the vector, because it occurred prior to and without the virus bolus. Animals infused with 1.5 g/kg and 3.0 g/kg RMP-7 survived the complete procedure. In these rats, X-Gal-positive tumor cells were predominantly seen in the periphery of the tumors, with less in the center and virtually none in the normal brain. There did not appear to be a significant difference in the amount or distribution of transgene expression in tumors infused with either 1.5 g/kg or 3.0 g/kg RMP-7. Therefore, the dose of 1.5 g/kg over 15 minutes was used for all further studies. Control animals receiving 1.5 g/kg RMP-7 or saline and saline injection (no virus) showed no X-Gal positivity within the tumor or the normal brain (Fig. 1A) . Animals infused with saline and bolused with virus demonstrated small numbers of stained cells in the periphery of the tumor and in normal and neoplastic capillaries.
Time course
To determine the peak time of HSV-mediated gene expression (e.g., the maximum extent of virus replication and spread within the tumor), 12 animals were infused with 1.5 g/kg RMP-7 or saline, injected with 1 ϫ 10 9 vector, and sacrificed at different timepoints. At 2 days after virus bolus (day 7), X-Gal staining was predominantly localized to the periphery of tumor masses (Fig.  1B) . The peak time for transgene expression in animals receiving RMP-7 was 3 days after virus bolus (day 8), with labeled tumor cells inside the tumor mass (Fig. 1C ) and in invading fronds (Fig. 1D ). On day 13 (8 days after virus bolus), viral gene expression was no longer evident in the main tumor mass but was seen in some small tumor fingers and microfoci that were distant from the main tumor mass.
Transgene expression in the above animals was also noted in peripheral organs (kidney, liver, and spleen) by lacZ and ICP4 staining. In the kidney, it was difficult to assess gene delivery of lacZ because control animals (no virus) showed extensive X-Gal staining; this staining was probably due to the natural acidity of this tissue, which favors staining by endogenous acidic ␤-gal. ICP4 immunostaining was seen in the kidney up to day 8 in virus-treated animals and was almost completely gone by day 13. At 1 day after virus bolus, there was evidence of transgene expression by X-Gal histochemical staining in the spleen but not in the liver that was confirmed by nearly identical ICP4 immunostaining. By day 13, there was little evidence of ICP4 gene expression in these peripheral tissues, nor was there any evidence of significant pathology, except rare small inflammatory infiltrates.
BK/RMP-7 comparison
To assess the role of these agents for modulation of the BTB and enhancement of vector transport into the tumor, RMP-7 and BK were compared. In addition, the influence of both large (1 mL) and small (0.1 mL) vector bolus volumes on tumor transduction rates was investigated. Six rats were used for this study and sacrificed at 2 days after virus injection for tissue processing. No significant differences were observed with regard to the extent of delivery to the tumor center or periphery as a function of BK or RMP-7 infusion or bolus volume (Fig. 2) .
DISCUSSION
This study demonstrates that the effects of an intracarotid infusion of RMP-7, a novel BK agonist, on HSV vector delivery to experimental brain tumors are equivalent to those previously demonstrated BK effects 24 and produce an enhancement of virus vector delivery. The delivery appears to be highest in the periphery of tumors and in infiltrating projections from the tumor and small foci. The pattern of viral delivery noted here, combined with the HSV-tk/GCV bystander activity, should help eradicate locally invasive tumor or micrometastases distal from the main tumor mass. RMP-7, like other vasoactive agents such as BK, histamine, and leukotrienes, 21, 22, 27, 35 can selectively open the BTB by increasing the permeability of brain tumor capillaries, which are morphologically different from normal brain capillaries. RMP-7 has been used previously to enhance the delivery of chemotherapeutic agents to brain tumors and is approved for human use. 28, 29 This is the first report of the use of intracarotid RMP-7 infusion to enhance the intra-arterial delivery of HSV vectors to experimental brain tumors.
There is presently no tumor model for malignant glioma that is histologically identical with human GBM. The syngeneic rat 9 L gliosarcoma model used in these studies was chosen to facilitate comparison with other HSV vector delivery studies that have used this model. 7, 15, 24 Most experimental models also differ from endogenous tumors in that they require an injection of tumor cells into the brain, which has the potential to disrupt normal parenchyma and induce glial scar forma- tion. To evaluate whether the act of implanting the tumor itself makes the BBB permeable, vehicle alone was injected into rat brain to cause the formation of glial scar followed by intra-arterial application of RMP-7 and virus. Expression of lacZ was limited to a few cells along the scar, presumably reactive astrocytes, both with and without RMP-7 infusion. The veracity of this lacZ staining was confirmed by immunohistochemical staining for ICP4, a virus-encoded protein; optimal conditions, pH, and length of incubation for X-Gal staining were used to reduce artifactual background staining. 32 The replication-conditional HSV vector used in this study, hrR3, replicates selectively within dividing cells, allowing for replication-conditional propagation within tumors in the brain. 7, 30 In animals bearing an established intracranial 9 L tumor and who received an infusion of RMP-7 and virus injection, transgene delivery was specific to and extensive in brain tumor tissue, whereas the normal brain showed minimal evidence of transgene expression. Tumor cells expressing the marker gene were concentrated in the tumor periphery. Peak expression occurred ϳ3 days after RMP-7-mediated BTB disruption and virus injection; this expression was no longer evident in the main tumor mass by 8 days, but lacZ expression continued in tumor fronds distal from the bulk of the tumor at this time. Presumably, these tumor fronds represent invasive, mitotic tumor cells that are able to complement the enzymatic deficiency of the replication-conditional virus vector. Although transgene expression was also evident in the spleen at 2 days after BTB disruption and virus injection, there was minimal evidence of pathological injury or ongoing infection with hrR3 by day 13. lacZ staining could not be evaluated in the kidney due to high background staining. No significant infection of the liver was noted at any timepoint.
Several characteristics of brain tumors may help to explain the initial distribution of virus within the periphery of the brain tumor following intracarotid RMP-7 infusion. The periphery of brain tumors has three distinguishing characteristics: it contains a higher density of blood vessels than the normal brain, 36 its blood vessels are more permeable than normal brain capillaries, 20 -22,25,35 and its interstitial fluid pressure is lower compared with the elevated level found in the center of tumors. 37 The high density of vessels in the tumor periphery would be expected to maximize blood flow into this area relative to that of surrounding brain parenchyma, thereby increasing the probability of vector entry. The increased permeability of tumor vessels, which is enhanced further by RMP-7, should also selectively increase the delivery of vector to tumors compared with the normal brain. Finally, the lower interstitial fluid pressure in the periphery of the tumor should facilitate the passage of the vector across the vasculature. The tumor periphery may be a particularly critical target, as this area contains the infiltrating tumor cells that escape treatment by conventional modalities. 23 In the present study, RMP-7 facilitated intra-arterial delivery of a replication-conditional HSV vector to the same extent and with the same pattern as the original nonapeptide BK, 24 although there are differences in the mode of action of these two substances. BK acts on both B 1 and B 2 receptors and causes hypotension, whereas RMP-7 is a selective B 2 receptor agonist without blood pressure effects. 25, 26 Furthermore, RMP-7 has longer half-life in the blood circulation; consequently, lower doses are needed compared with BK. In addition, the present studies show that comparable delivery is possible using a smaller volume (0.1 mL) of vehicle for vector application compared with the 1.0 mL volume used in a previous study, 24 without compromising the degree of vector delivery to the tumor.
In some instances in the present study, when virus was injected without BTB modification, gene expression was also seen selectively within tumors and not in the normal brain. This result is probably not surprising given the large load of virus that was injected and the somewhat leaky nature of the BTB itself. 26, 27 Clearly, however, intracarotid infusion of RMP-7 augmented the delivery of virus to experimental brain tumors without increasing the amount of virus delivered to the normal brain. Importantly, disruption of the BTB using RMP-7 promotes vector uptake into the infiltrating edge of brain tumors, which is an area that is difficult to distinguish from the normal brain by the conventional treatment modalities of surgery, chemotherapy, or radiation. 2 Systemic toxicity of the virus was minimal in the immunocompetent animals used in the present study. Intraarterial delivery of virus with BTB modification might also be effective in delivery to the smaller vessels feeding the tumor by an interventional endovascular approach. In all cases (A-D) , the tumor periphery showed an increased uptake of virus compared with the central region. There was no statistically significant difference between BK and RMP-7 in terms of BTB modulation, using either large or small bolus volumes of virus (P Ͼ .05).
The increased vascularization of human gliomas should enhance intra-arterial vector delivery, although this approach would probably not be effective alone without prior surgical debulking of highly malignant tumors, such as GBM. Intra-arterial delivery of virus vectors with pharmacological BTB modification may prove especially useful in the treatment of surgically inaccessible tumors, such as deep cortical gliomas or pediatric pontine gliomas.
